Chondroitin: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett |
imported>Meg Taylor (subpages) |
||
| Line 1: | Line 1: | ||
{{subpages}} | |||
In [[biochemistry]], '''chondroitin''' is a "mucopolysaccharide constituent of chondrin."<ref>{{MeSH}}</ref> | In [[biochemistry]], '''chondroitin''' is a "mucopolysaccharide constituent of chondrin."<ref>{{MeSH}}</ref> | ||
Revision as of 04:52, 30 September 2009
In biochemistry, chondroitin is a "mucopolysaccharide constituent of chondrin."[1]
Clinical studies
Chondroitin has been studied as a treatment for osteoarthritis. A meta-analysis of randomized controlled trials found no benefit.[2] This meta-analysis included the GAIT randomized controlled trial of Clegg et al that was sponsorered by the U.S. National Institutes of Health.[3] A longer followup of the GAIT show no benefit from sodium chondroitin on reduction in loss of joint space width.[4]
A more recent trial is positive. A trial sponsored by the manufacturer reports less loss of joint space with chondroitins 4 and 6.[5]
| Trial | Patients | Intervention | Outcome | Results | |
|---|---|---|---|---|---|
| Chondroitin | Placebo | ||||
| GAIT[3] 2007 |
1583 patients with knee osteoarthritis | 1200 mg of chondroitin sulfate daily | Response of 20% decrease in WOMAC pain score[6] at 24 weeks | All subjects: 65% Mild OA: 67% Moderate/severe OA: 61%‡ |
All subjects: 60% Mild OA: 62% Moderate/severe OA: 54% |
| GAIT[4] 2008 |
1583 patients with knee osteoarthritis | 1200 mg of chondroitin sulfate daily | Loss of joint space width at two years | 0.107 mm | 0.166 mm |
| Kahan[5] 2009 Sponsored by manufacturer and trial registration not provided |
622 patients with knee osteoarthritis 32% dropped out |
800 mg of chondroitin sulfate daily | Loss at minimum joint space width Used last observation carried forward for dropouts |
0.07 mm† | 0.31 mm |
| † p < 0.05 ‡ All comparisons were insignificant and less than occurred with celecoxib; however, the combination of glucosamine hydrochloride and chondroitin gave significant 79% improvement among moderate/severe patients. However, longer follow-up of GAIT showed the combination group tended to have the most loss of joint space.[4] | |||||
References
- ↑ Anonymous (2024), Chondroitin (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Reichenbach S, Sterchi R, Scherer M, et al (2007). "Meta-analysis: chondroitin for osteoarthritis of the knee or hip". Ann. Intern. Med. 146 (8): 580-90. PMID 17438317. [e]
- ↑ 3.0 3.1 Clegg DO, Reda DJ, Harris CL, et al (February 2006). "Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis". N. Engl. J. Med. 354 (8): 795–808. DOI:10.1056/NEJMoa052771. PMID 16495392. Research Blogging.
- ↑ 4.0 4.1 4.2 Sawitzke AD, Shi H, Finco MF, et al (October 2008). "The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial". Arthritis Rheum. 58 (10): 3183–91. DOI:10.1002/art.23973. PMID 18821708. Research Blogging.
- ↑ 5.0 5.1 Kahan A, Uebelhart D, De Vathaire F, Delmas PD, Reginster JY (February 2009). "Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: The study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial". Arthritis Rheum. 60 (2): 524–33. DOI:10.1002/art.24255. PMID 19180484. Research Blogging. Trial registration not provided. Summary at JournalWatch.org
- ↑ Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW (December 1988). "Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee". J. Rheumatol. 15 (12): 1833–40. PMID 3068365. [e]